Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 9/20 | 0.50 |
| ▸ | HTR3A | P46098 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516777 | 0.86 | CHEK1 (0.49) | CHEK1CACNA1GHTR3AKMT2AMEN1 | |
| SCHEMBL6509536 | 0.83 | CHEK1 (0.58) | CHEK1CACNA1GHTR3AKMT2AMEN1 | |
| SCHEMBL6522894 | 0.81 | CHEK1 (0.65) | CHEK1 | |
| SCHEMBL6523103 | 0.81 | CHEK1 (0.55) | CHEK1MAPTALDH1A1 | |
| SCHEMBL6514143 | 0.81 | CHEK1 (0.57) | CHEK1CACNA1GHTR3AKMT2AMEN1 | |
| SCHEMBL6046793 | 0.80 | CHEK1 (0.50) | CHEK1 | |
| SCHEMBL6515407 | 0.77 | CHEK1 (0.71) | CHEK1 | |
| SCHEMBL6513032 | 0.76 | CHEK1 (0.53) | CHEK1MAPTALDH1A1GAA | |
| SCHEMBL6515415 | 0.75 | CHEK1 (0.58) | CHEK1 | |
| SCHEMBL6515699 | 0.74 | CHEK1 (0.55) | CHEK1KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885CACNA1G 3988/4885HTR3A 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.